

# NIH Public Access

Author Manuscript

*Arch Intern Med.* Author manuscript; available in PMC 2009 September 16.

Published in final edited form as:

Arch Intern Med. 2009 February 9; 169(3): 269–278. doi:10.1001/archinternmed.2008.545.

# Exercise dose and quality of life: Results of a randomized controlled trial

Corby K. Martin, PhD<sup>1</sup>, Timothy S. Church, MD, MPH, PhD<sup>1</sup>, Angela M. Thompson, MSPH<sup>1</sup>, Conrad P. Earnest, PhD<sup>1</sup>, and Steven N. Blair, PED<sup>2,3</sup>

<sup>1</sup>Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana

<sup>2</sup>Arnold School of Public Health, University of South Carolina, Columbia, South Carolina

<sup>3</sup>Department of Kinesiology, Health Promotion, and Recreation, University of North Texas, Denton, Texas

# Abstract

**Background**—Improved quality of life (QOL) is a purported benefit of exercise despite few randomized controlled trials (RCTs) and no dose-response trials.

**Methods**—The effect of 50%, 100%, and 150% of the NIH Consensus Development Panel physical activity dose on QOL was examined in a six-month RCT. Participants were 430 sedentary postmenopausal women (BMI 25.0-43.0 kg/m<sup>2</sup>) with elevated systolic blood pressure randomized to a non-exercise control group (n=92) or 1 of 3 exercise groups: exercise energy expenditure of 4 (n=147), 8 (n=96), or 12 (n=95) kcal/kg/week. Eight aspects of physical and mental QOL were measured at baseline and month 6 with the SF-36.

**Results**—Change in all mental and physical aspects of QOL, except body pain, was dose-dependent (trend analyses were significant and exercise dose was a significant predictor of QOL change; p-values<0.05). Change (95% confidence interval) in QOL for the control, 4, 8, and 12 kcal/kg/week groups, respectively, were: physical functioning 2.5 (-0.1-5.1), 4.7 (2.7-6.8), 6.3 (3.7-8.8), 8.2 (5.6-10.7); role physical 2.6 (-2.7-7.9), 8.9 (4.8-13.1), 9.7 (4.5-14.8), 13.1 (7.8-18.3); bodily pain 2.6 (-1.0-6.3), 4.1 (1.3-7.0). 2.4 (-1.1-6.0), 6.8 (3.3-10.4); general health 1.5 (-0.8-3.9), 5.5 (3.6-7.4), 4.7 (2.4-7.1), 7.8 (5.4-10.1); mental health 0.6 (-1.4-2.6), 4.4 (2.8-6.0), 3.6 (1.6-5.5), 4.2 (2.2-6.2); role emotional 4.2 (-0.5-8.9), 8.6 (4.9-12.3), 9.4 (4.8-14.0), 14.6 (9.9-19.2); social functioning -0.4 (-3.3-2.5), 4.5 (2.2-6.8), 5.0 (2.1-7.9), 8.7 (5.9-11.6); vitality 4.6 (1.6-7.6), 9.8 (7.5-12.2), 9.1 (6.1-12.0), 11.7 (8.8-14.7). Controlling for weight change did not attenuate the exercise-QOL association.

**Conclusion**—Exercise-induced QOL improvements were dose-dependent and independent of weight change.

# Keywords

Quality of Life; physical activity; dose-response; exercise training; SF-36

Address for correspondence and reprints: Corby K. Martin, Ph.D., Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, Louisiana 70808, Email: Corby.Martin@pbrc.edu, Phone: 225-763-2585, Fax: 225-763-3045.

Preliminary results from this study were presented at the American Heart Association's Nutrition, Physical Activity and Metabolism Conference, Colorado Springs, CO (March 13, 2008).

A sedentary lifestyle is a risk factor for many chronic conditions including diabetes, heart disease, stroke, and certain types of cancers.<sup>1-6</sup> Regular physical activity and higher levels of cardiorespiratory fitness are associated with lower risk for premature mortality, and exercise training has been demonstrated to improve a number of important risk factors such as cardiorespiratory fitness,<sup>7</sup> weight, HDL cholesterol, and fasting insulin.<sup>8</sup> Though mood, level of functioning, energy level, and other measures of quality of life (QOL) are purported to be improved by regular exercise, this claim is largely unsubstantiated in populations without significant morbidities. There is strong evidence that regular exercise substantially improves QOL in populations with serious diseases such as cancer<sup>9</sup> or chronic obstructive pulmonary disease, <sup>10</sup> but the data are not as supportive in populations without disease. Although many, but not all, epidemiology studies have found an association between exercise and QOL, the available data from intervention trials fail to consistently find a strong effect of exercise training on OOL.<sup>11, 12</sup> Further, the data from intervention trials are difficult to interpret due to small sample sizes, inadequate control groups, poor exercise compliance, and many studies included a weight loss component making it difficult to separate the benefits of weight loss from increased exercise.

To our knowledge, there are no well-controlled, properly powered randomized controlled trials (RCTs) examining the role of exercise at improving QOL among individuals without significant comorbidities. The Dose-Response to Exercise in postmenopausal Women (DREW) study was designed to examine the health benefits of 50%, 100%, and 150% of the NIH Consensus Panel<sup>13</sup> physical activity recommendation in 464 sedentary, overweight or obese, postmenopausal women with elevated blood pressure. The primary outcomes of cardiorespiratory fitness and blood pressure have been reported,<sup>7</sup> but data on a number of important secondary outcomes also were included a priori in the study design, and these included a QOL survey.<sup>14</sup> Given the relatively large sample size, very high compliance to a tightly controlled exercise intervention, and the high participant retention rate, DREW provides an excellent opportunity to examine the effects of exercise on QOL. Identifying a dose-response relation between exercise and QOL could not only help determine minimum exercise thresholds for promoting QOL, but increase assurance that the exercise-induced benefits are not spurious or the result of chance alone. Thus, the primary aim of this study was to examine changes in QOL across different doses of supervised exercise. We hypothesized that sixmonths of structured moderate intensity exercise would significantly improve QOL in a dose dependent manner.

# METHODS

### Study Design

A complete description of the DREW study design and methods has been published elsewhere. <sup>7, 14</sup> In brief, the study was a randomized dose-response exercise trial with a non-exercise control group and three exercise groups with incrementally higher doses of energy expenditure. The non-exercise control group was asked to maintain their baseline level of activity during the six-month study period. The research protocol was reviewed and approved annually by The Cooper Institute Institutional Review Board. Written informed consent was obtained from all participants prior to their participation.

### **Study Participants**

Thorough descriptions of the recruiting, screening process, and methods have been published. <sup>7, 14</sup> Briefly, the study was limited to postmenopausal women age 45 to 75 years who were sedentary (not exercising more than 20 minutes on 3 or more days a week, and < 8000 steps per day assessed over the course of one week), overweight or obese (BMI 25.0 to 43.0 kg/m<sup>2</sup>), and who had a systolic blood pressure of 120.0 to 159.9 mm Hg. Exclusion criteria

included history of stroke, heart attack, diabetes, or any medical condition that prevented participants from adhering to the protocol or exercising safely. Women with a score  $\geq 10$  on the Center for Epidemiological Studies Depression scale (CES-D)<sup>15</sup> were excluded based data from our laboratory indicating that these women have a greater probability of attrition and other studies demonstrating that depressed mood is associated with attrition from exercise programs that are part of weight loss programs <sup>16</sup> and cardiac rehabilitation <sup>17</sup>. Participants were recruited from the Dallas, Texas area from April 2001 to June 2005.

#### Outcomes

Change in QOL was measured with the Medical Outcomes Study Short-Form 36 Health Survey (SF-36).<sup>18, 19</sup> The SF-36 is a self-administered 36-item questionnaire that measures physical and mental QOL. Physical QOL is measured with the following four scales: physical functioning (PF), role limitations due to physical problems (Role-Physical or RP), bodily pain (BP), and general health perception (GH). Mental QOL also is measured with four scales: role limitations due to emotional problems (Role-Emotional or RE), social functioning (SF), vitality (VT), and mental health (MH). The validity and reliability of the SF-36 have been established and there are standardized norms available for comparative purposes.<sup>18, 19</sup> Participants' raw scores were converted into scale scores ranging from 0 to 100, with higher scores representing better QOL or higher functioning for all scales.

#### **Other Measures**

Maximal fitness testing was conducted using a Lode Excalibur Sport cycle ergometer (Groningen, Netherlands) with respiratory gases measured using a Parvomedics True Max 2400 Metabolic Measurement Cart. Weight was measured on an electronic scale (Siemens Medical Solutions, Malvern, PA) and height was measured using a stadiometer. Body mass index (BMI) was calculated as weight in kilograms, divided by height in meters squared. Smoking history, medical history and medication use were assessed by detailed questionnaires. Blood pressure was measured a using a Colin STBP-780 automated blood pressure unit with participants in the recumbent position. Detailed descriptions of the testing procedures are provided elsewhere.<sup>7, 14</sup>

# **Exercise Training**

Women were assigned to either a non-exercise control group or to groups that expended 4, 8, or 12 kilocalories per kilogram body weight per week (KKW), which corresponds to 50%, 100% and 150%, respectively, of current public health physical activity recommendations.<sup>13</sup> Smaller changes in study endpoints were expected in the 4 KKW group; therefore, randomization procedures were created to assign more participants to that group based on the recommendation of the study biostatistician. Exercising women participated in 3 or 4 training sessions each week for 6 months with training intensity at the heart rate associated with 50% of each woman's peak VO<sub>2</sub>. All exercise sessions were performed under observation and supervision in an exercise laboratory with standardized prescriptions for exercise dose and strict monitoring of the amount of exercise completed in each session. Participants were weighed each week and their weight was multiplied by their exercise dosage to determine the number of calories to be expended for the week. Women in the exercise groups alternated training sessions on semi-recumbent cycle ergometers and treadmills. Adherence to exercise training over the entire 6-month period was calculated for each individual by dividing the kcal expended during the exercise training by the kcal prescribed for the training period multiplied by 100.

#### Participant Retention, Adherence, Blinding, and Randomization

A detailed description of procedures for participant retention, adherence, blinding, and random assignment are provided elsewhere.<sup>7, 14</sup> To facilitate retention and adherence, participants completed a two-week pre-randomization run-in period and they signed behavioral contracts in which they agreed to adhere to the study protocol. Participants were compensated \$150 (total) for completion of baseline (\$75) and follow-up (\$75) assessments. An additional \$350 in incentives was available based on adherence. Assessment personnel were blind to treatment assignment, although blinding was not possible for intervention personnel. Participants were reminded not to discuss their group assignment with the assessment team. Randomization assignment was computer generated and conducted by the statistician.<sup>14</sup>

## **Statistical Analysis**

Descriptive baseline characteristics of groups were tabulated as means and standard deviations (SD) or as percentages. Differences on baseline SF-36 scale scores among specific subgroups (ethnicity/race, age group, smoking status, marital status, antidepressant use, employment status, and BMI range) were evaluated with analysis of variance (ANOVA), with post-hoc tests when appropriate.

Dose-response effects were evaluated with regression analysis to test for trends in QOL change across groups with adjustment for pre-specified covariates that were identified with the subgroup analysis mentioned above (ethnicity, age group, smoking status, marital status, antidepressant use, employment status, and BMI range). Differences in QOL change across groups were tested by analysis of covariance (ANCOVA) with adjustment. For statistically significant ANCOVAs (p<.05), pair-wise comparisons between exercise groups and the control group were made using the Bonferroni correction for multiple testing. An alpha level of 0.0167 (.05/3 = 0.0167) was utilized because it was our *a priori* intention to compare only the differences between the exercise groups and the control group; hence, p-values were multiplied by three and reported using the following notations: \*p<.05, \*\*p<.01, \*\*\*p<.001. Results are presented as adjusted least-squares means with 95% confidence intervals.

Analyses were limited to participants with baseline data. If the outcome value was missing for the participant, we inserted the baseline value for that outcome (i.e., last observation carried forward). Any QOL values > 3 standard deviations from the mean were defined as outliers and eliminated. For exploratory purposes, all QOL outcomes were tested using only available data, without using baseline values carried forward for missing follow-up data. The results from these analyses did not differ substantially from the analyses with baseline values carried forward (the primary analyses); therefore, only the primary analyses are presented. All reported p-values are two-sided. All analyses were performed using SAS version 9.1 (Cary, NC).

# RESULTS

A total of 4545 telephone screens were conducted and 4081 potential participants were ineligible based on inclusion and exclusion criteria (Figure 1). After giving informed consent, 464 were randomized, of which 432 had complete QOL data at baseline and 398 of these participants completed the study with 356 usable follow-up QOL surveys. Baseline values were carried forward for missing data/drop-outs, resulting in 430 participants' data included in the primary analyses. Two participants' data in the 4 KKW group were eliminated due to being outliers.

As summarized in Table 1, the study population had a mean (SD) age of 57.4 (6.5), a mean BMI of  $31.8 (3.8) \text{ kg/m}^2$ , and 34.9% were non-Caucasian. Almost 30% of the study population reported a history of depression with 18.2% taking anti-depressant medication at baseline. Only

4.4% of the participants were current smokers and 76.5% were employed. Almost half of the participants were using hormone therapy and 15.2% were taking thyroid medication. With the exception of blood pressure, as a group the cardiovascular risk factors were in normal ranges. The mean baseline peak VO<sub>2</sub> was very low at 15.4 (2.9) ml/kg/min (see Table 2). Adherence to exercise was 95.4%, 88.1%, and 93.7% across the 4, 8 and 12 KKW groups and each group spent 73.9, 138.3, and 183.6 minutes per week exercising, respectively (Table 2).

The mean baseline scores for QOL scales for the total population and by group are presented in Table 1. As illustrated in Figure 2, the DREW sample at baseline had scores similar to the general United States (U.S.) population<sup>20</sup>. The mean QOL scores for the DREW sample differed from the national mean by only 0.02 to 0.22 standard deviation units, which are considered differences of small magnitude <sup>21</sup>. The mean baseline scores for QOL scales across specific subgroups are presented in Table 3, and, although some comparisons had small sample size, these data demonstrate that we observed many of the expected QOL differences among groups. For example, QOL at baseline was lower on all scales among participants taking antidepressant medication compared to participants not taking such medication. Additionally, employed participants reported better QOL on the PF, RP, and BP scales.

Figure 3 summarizes the mean change in SF-36 measures across the control and exercise groups. The positive linear trend across groups was statistically significant for all physical and mental QOL scales (all p-values < 0.0001), with exercise dose being a significant independent predictor of change in all QOL scales (p-values ranged from < 0.0001 to 0.04), except bodily pain (p=0.19). Thus, a dose-response effect of exercise on QOL was noted for all aspects of QOL except bodily pain. The ANCOVAs indicated that for all physical and mental QOL scales, except BP (p=0.32), the 12 KKW group significantly improved QOL compared to the control (p-values ranged from <0.001 to 0.04). Additionally, the 4 KKW group significantly improved GH, VT, and MH compared to control (p-values 0.01 to 0.04). All three exercise groups significantly improved SF compared to control (p-values < 0.0001 to 0.03). The analyses were conducted without the aforementioned covariates and the results were virtually identical.

The mean change in weight across the control, 4 KKW, 8 KKW and 12 KKW groups was -0.94 (4.0), -1.34 (3.5), -1.86 (3.4), and -1.34 (2.9) kg, respectively, with no between group differences. To examine the effect of weight loss on improvement in SF-36 measures, all analyses were repeated with additional adjustment for change in body weight. Weight change was a significant covariate in only two of the eight comparisons and inclusion of this covariate did not have a meaningful effect on any of the mean values, significance, nor trends across exercise groups. To further assure that weight loss was not responsible for the observed results, change in SF-36 scores across the exercise groups was examined with participants sub-grouped into those who lost weight and those who maintained or gained weight. Figure 4 summarizes the change in SF-36 scores across for the SF-36 scales ranged from 0.07 to 0.95. These non-significant interactions indicate that the pattern of change in each of the SF-36 measures across the exercise groups was similar for those who did and did not lose weight.

All analyses were repeated with change in fitness as a covariate, and the conclusions from these analyses were not meaningfully affected. Change in fitness was also correlated with change in QOL and only two of the eight correlation coefficients differed significantly from zero and the size of the coefficients was small (Physical Functioning, r=.11, p=.02; Role Physical, r=.12, p=.02). These findings suggest that changes in fitness are not necessary to improve QOL when individuals increase physical activity.

To explore the effect of antidepressant use on the results, participants were sub-grouped by antidepressant use (yes/no), and change in QOL among exercise groups was tested with an

exercise group by sub-group interaction. The interaction term was not significant for all four physical measures of QOL (p-values > .11), but it was significant for the Role Emotional, Social Functioning, and Vitality scales (the p-value for the Mental Health scale approached significance; p=.06). These findings and examination of group means indicated that participants in the non-exercise control condition who took antidepressant medication experienced no increase in QOL during the trial, and for some mental QOL measures they experienced decreased QOL. Conversely, control participants who were not taking antidepressant medication experienced small increases in QOL during the trial.

# COMMENT

The primary finding from this randomized controlled exercise trial was a significant, positive dose-response relation between the amount of exercise performed and improvements in measures of both physical and mental QOL. While improved quality life is routinely cited as a benefit of regular exercise, data to support this claim are limited to conflicting epidemiology reports or from studies in persons diagnosed with major chronic diseases such as cancer. Though not observed for all measures, it is of interest that even 4 KKW of exercise (approximately 74 min per week) was associated with a significant improvement in QOL for several of the QOL scales as compared with women in the non-exercise control group. It is noteworthy that the improvements in QOL occurred at a modest training intensity (heart rate at 50% peak VO<sub>2</sub>) and, as demonstrated by our low dropout rate and excellent adherence in all exercise groups to the six-month caloric expenditure target, the exercise prescriptions were well-tolerated by participants. As a consequence of randomizing more participants to the 4 KKW group, statistical power was sufficient to detect differences in QOL change between the control and 4 KKW group, but not the control and 8 KKW group, despite very similar effect sizes. The significant trend (regression) analyses confirm the dose-response effect, however.

Most cross-sectional studies have observed higher levels of activity to be associated with higher QOL scores, <sup>12</sup> particularly for physical aspects of QOL.<sup>22</sup> However, in one cross-sectional study, extended bouts of exercise were associated with poor QOL.<sup>23</sup> Prospective observational studies suggest that people who report higher levels of exercise also report higher QOL scores, at least among women.<sup>24</sup> Nonetheless, as in all observational studies, causation cannot be implied from these findings and it is easy to hypothesize that people with a higher perceived QOL are more like to be physically active or more likely to increase their level of exercise. To our knowledge, we are the first to demonstrate in an RCT that instituting a regular exercise program results in significant improvements in both mental and physical QOL and that these improvements are sensitive to exercise dose; i.e., dose-dependent. The robust effect of exercise on mental QOL in the present study is of interest, since cross-sectional studies find an association primarily between physical aspects of QOL and exercise. It is also of interest that physical activity induced changes in QOL were independent of changes in fitness, suggesting that changes in fitness are not requisite for physical activity induced improvements in QOL.

In an uncontrolled weight loss study, which included exercise, weight loss and/or exercise was associated with improved QOL,<sup>25</sup> and a prospective observational study supports the hypothesis that weight loss among overweight women is associated with improved QOL.<sup>26</sup> The findings from DREW provide insight into the relative importance of weight loss in exercise-induced changes in QOL, as weight loss in DREW was small and did not differ significantly among the groups. Moreover, exercise induced improvements in QOL were independent of weight loss and the magnitude of change in QOL was similar among those that did and did not lose weight. These results support the hypothesis that exercise in the absence of substantial weight loss can significantly improve both physical and mental QOL.

The public health implications of our findings are significant. We are in the midst of a large shift in the demographics of the U.S. with the proportion of Americans over age 65 growing dramatically over the next few decades. While maximizing longevity is of great importance, maximizing QOL should also be a priority. Our findings suggest that increasing physical activity is an effective tool to improve QOL. Increasing exercise, particularly as individuals age, has many health benefits, e.g., cardiovascular disease (CVD) risk factors are reduced,<sup>7,8</sup> and our results indicate that improved QOL can be added to the list of benefits of exercise, and that these improvements are dose-dependent and independent of weight loss, at lease in people similar to this study sample.

### Limitations and Strengths

The study has limitations because its sample was limited to sedentary, overweight or obese, postmenopausal women at risk for CVD. Thus, we do not know if the results will apply to other women or men. Nonetheless, the study sample was a group that would likely benefit from exercise training and represents a sizeable proportion, probably a majority, of U.S. women in the age range of 45 to 75 years. Further, although baseline SF-36 scores were similar to the national mean, baseline QOL scores were high, yet we were able to detect significant improvements in QOL. Because participants assigned to incrementally higher doses of exercise spent more time exercising at the center, they had more contact with study personnel and this contact could have influenced QOL. However, in the only other RCTs testing if exercise affects QOL<sup>11</sup>, the amount of contact between study personnel and participants varied systematically among the study groups, yet no consistent effect of exercise on QOL was found, suggesting that contact with study personnel has little effect on QOL. Lastly, the DREW study was not designed specifically to evaluate the effect of exercise on QOL, however, QOL measures were pre-planned secondary outcomes and this RCT provides compelling evidence of the dose-response relation between exercise and improved QOL.

The study reported herein has many strengths, including being an RCT with three different exercise doses and with all exercise completed in the laboratory. Our study had a large proportion of non-Caucasian participants (primarily African-American), and exercise energy expenditure, heart rate, and steps taken during exercise on the treadmill were extensively monitored. Exercise adherence was excellent, the dropout rate was low, and baseline SF-36 values were similar to the national mean for the U.S. Additionally, expected differences on baseline QOL scores were observed among subgroups, including BMI category and employment status. The exercise doses, including intensity, are easily obtainable and were well tolerated by sedentary women, resulting in confidence that the exercise doses utilized in this study can be achieved by women in the community.

# CONCLUSIONS

In this study of previously sedentary, overweight or obese, postmenopausal women, exercise improved both physical and mental QOL in a dose dependent fashion, and the improvements in QOL were independent of weight loss.


# Acknowledgments

This work was performed at The Cooper Institute, and the staff is especially commended for their efforts. We thank The Cooper Institute Scientific Advisory Board and the DREW participants.

# References


- Blair SN, Kohl HW 3rd, Barlow CE, Paffenbarger RS Jr, Gibbons LW, Macera CA. Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men. JAMA 1995;273:1093–1098. [PubMed: 7707596]
- Blair SN, Kohl HW 3rd, Paffenbarger RS Jr, Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA 1989;262:2395–2401. [PubMed: 2795824]
- 3. Gulati M, Pandey DK, Arnsdorf MF, et al. Exercise capacity and the risk of death in women: The St James Women Take Heart Project. Circulation 2003;108:1554–1559. [PubMed: 12975254]
- Mora S, Redberg RF, Cui Y, et al. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: A 20-year follow-up of the lipid research clinics prevalence study. JAMA 2003;290:1600–1607. [PubMed: 14506119]
- Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002;346:793–801. [PubMed: 11893790]
- Stevens J, Evenson KR, Thomas O, Cai J, Thomas R. Associations of fitness and fatness with mortality in Russian and American men in the lipids research clinics study. Int J Obes Relat Metab Disord 2004;28:1463–1470. [PubMed: 15365584]
- Church TS, Earnest CP, Skinner JS, Blair SN. Effects of different doses of physical activity on cardiorespiratory fitness among sedentary, overweight or obese postmenopausal women with elevated blood pressure: A randomized controlled trial. JAMA 2007;297:2081–2091. [PubMed: 17507344]
- Cornelissen VA, Fagard RH. Effects of endurance training on blood pressure, blood pressure-regulating mechanisms, and cardiovascular risk factors. Hypertension 2005;46:667–675. [PubMed: 16157788]
- Burnham TR, Wilcox A. Effects of exercise on physiological and psychological variables in cancer survivors. Med Sci Sports Exerc 2002;34:1863–1867. [PubMed: 12471288]
- Emery CF, Schein RL, Hauck ER, MacIntyre NR. Psychological and cognitive outcomes of a randomized trial of exercise among patients with chronic obstructive pulmonary disease. Health Psychol 1998;17:232–240. [PubMed: 9619472]
- de Vreede PL, van Meeteren NL, Samson MM, Wittink HM, Duursma SA, Verhaar HJ. The effect of functional tasks exercise and resistance exercise on health-related quality of life and physical activity. A randomised controlled trial. Gerontology 2007;53:12–20. [PubMed: 16940735]
- Spirduso WW, Cronin DL. Exercise dose-response effects on quality of life and independent living in older adults. Med Sci Sports Exerc 2001;33:S598–608. [PubMed: 11427784]discussion S609-510
- Physical activity and cardiovascular health. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. JAMA 1996;276:241–246. [PubMed: 8667571]
- Morss GM, Jordan AN, Skinner JS, et al. Dose Response to Exercise in Women aged 45-75 yr (DREW): design and rationale. Med Sci Sports Exerc 2004;36:336–344. [PubMed: 14767260]
- 15. Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. Applied Psychological Measurement 1977;1:385–401.
- Clark MM, Niaura R, King TK, Pera V. Depression, smoking, activity level, and health status: pretreatment predictors of attrition in obesity treatment. Addict Behav 1996;21:509–513. [PubMed: 8830908]
- Ziegelstein RC, Fauerbach JA, Stevens SS, Romanelli J, Richter DP, Bush DE. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch Intern Med 2000;160:1818–1823. [PubMed: 10871976]
- Ware, JE., Jr; Kosinski, M.; Gandek, B. SF-36 Health Survey: Manual & Interpretation Guide. Lincoln, RI: QualityMetric Inc; 1993. p. 2002
- 19. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–483. [PubMed: 1593914]
- 20. Ware, JE., Jr; Kosinski, M. SF-36 Physical & Mental Health Summary Scales: A Manual for Users of Version 1. Vol. Second Edition. Lincoln, RI: QualityMetric Incorporated; 2001.
- 21. Cohen, J. Statistical power analysis for the behavioral sciences. Vol. 2. New Jersey: Lawrence Erlbaum; 1988.

- Wendel-Vos GC, Schuit AJ, Tijhuis MA, Kromhout D. Leisure time physical activity and healthrelated quality of life: cross-sectional and longitudinal associations. Qual Life Res 2004;13:667–677. [PubMed: 15130029]
- 23. Brown DW, Brown DR, Heath GW, et al. Associations between physical activity dose and healthrelated quality of life. Med Sci Sports Exerc 2004;36:890–896. [PubMed: 15126726]
- 24. Wolin KY, Glynn RJ, Colditz GA, Lee IM, Kawachi I. Long-term physical activity patterns and health-related quality of life in U.S. women. Am J Prev Med 2007;32:490–499. [PubMed: 17533064]
- Fontaine KR, Barofsky I, Andersen RE, et al. Impact of weight loss on health-related quality of life. Qual Life Res 1999;8:275–277. [PubMed: 10472159]
- 26. Fine JT, Colditz GA, Coakley EH, et al. A prospective study of weight change and health-related quality of life in women. JAMA 1999;282:2136–2142. [PubMed: 10591335]




# Figure 1.

CONSORT diagram describing recruitment and retention of participants. \*Baseline values were carried forward if follow-up QOL scores were missing.



#### Figure 2.


Mean ( $\pm$  SD) baseline SF-36 scores for the DREW sample and the national mean for the United States. The mean QOL scores for the DREW sample differed from the national mean by only 0.02 to 0.22 standard deviation units, which are considered differences of small magnitude <sup>21</sup>.



#### Figure 3.

Mean change (Least-squares means  $\pm$  95% confidence interval) on SF-36 measures across the control and exercise groups. The dose-response relations between exercise dose and change in QOL were evaluated with regression analysis to test for trends in QOL change across groups. Significant trends were found for all QOL scales (all p-values < 0.0001), with exercise dose being an independent predictor of change in PF, t(1) = 3.19, p=0.002; RP, t(1) = 2.62, p=0.009; GH, t(1) = 3.21, p=0.001; MH, t(1) = 2.03, p=0.044; RE, t(1) = 3.00, p=0.003; SF, t(1) = 4.17, p<0.0001; and VT, t(1) = 2.88, p=0.004; but not BP, t(1) = 1.31, p=0.192. Differences in QOL change across groups were tested by analysis of covariance (ANCOVA) with adjustment for pre-specified covariates (age, antidepressant use, BMI, employment status, ethnicity, marital

status, and smoking status at baseline). Significant ANCOVAs (p < .05) were followed by pairwise comparisons to test if the exercise groups differed significantly from the control group. The alpha level was set a 0.0167 (.05/3=0.0167) and all p-values were multiplied by three; hence, the following notation was used to depict statistical significance: \*p < .05, \*\*p < .01, \*\*\*p < .001. For significant comparisons, the LS mean differences (95% confidence intervals) between the 12 KKW and control group follow: PF 5.7 (1.2-10.2), RP 10.4 (1.3-19.5), GH 6.2 (2.1-10.4), MH 3.6 (0.2-7.1), RE 10.4 (2.3-18.4), SF 9.1 (4.1-14.2), and VT 7.1 (1.9-12.2). Similarly, significant LS mean differences (95% CI) between the 4 KKW and control group were: GH 3.9 (0.2-7.6), VT 5.2 (0.5-9.9), SF 4.9 (0.3-9.4), and MH 3.8 (0.7-6.9). The 8 KKW significantly improved SF compared to control 5.4 (0.4-10.4).



#### Figure 4.

Change in SF-36 scores across the exercise groups was examined for two subgroups of participants: 1) those who lost weight vs. 2) those who maintained or gained weight, using analysis of covariance (ANCOVA) with baseline age, antidepressant use, employment status, ethnicity, marital status, and smoking status as covariates. Mean change (Least-squares means  $\pm$  95% confidence interval) on SF-36 scales across the control and exercise groups for participants who did and did not lose weight are depicted. The results from the ANCOVAs follow: PF, F(3, 416) = 0.12, p=0.95; RP, F(3, 416) = 1.00, p=0.39; BP, F(3, 416) = 1.41, p=0.24; GH, F(3, 416) = 0.28, p=0.84; MH (3, 416) = 0.18, p=0.91; RE, F(3, 416) = 2.41, p=0.07; SF, F(3, 416) = 0.87, p=0.46; and VT, F(3, 416) = 0.11, p=0.95. These non-significant

interactions indicate that the pattern of change in each of the SF-36 measures across the exercise groups was similar for those who did and did not lose weight.

~
~
_
_
_
U .
Author
-
<u> </u>
-
_
0
-
•
_
~
$\geq$
<u> </u>
=
-
C
S S
õ
0
uscri
0
<b>_</b>

Table 1

Martin et al.

Baseline characteristics of the study sample.

			Rand	Randomization Groups	
Characteristics	All participants (n= 430)	Control (n=92)	4 kcal/kg/wk (n= 147)	8 kcal/kg/wk (n=96)	12 kcal/kg/wk (n=95)
Demographics					
Age, y	57.4 (6.5)	57.1 (6.0)	57.9 (6.6)	57.7 (6.6)	56.5 (6.7)
Education, No. (%)					
<12 yrs	12 (2.8)	3 (3.3)	4 (2.7)	3 (3.1)	2 (2.1)
12-16 yrs	295 (68.6)	66 (71.7)	103 (70.1)	63 (65.6)	63 (66.3)
>16 yrs	123 (28.6)	23 (25.0)	40 (27.2)	30 (31.3)	30 (31.6)
Married, No. (%)	393 (91.4)	86 (93.5)	138 (93.9)	85 (88.5)	84 (88.4)
Ethnicity, No. (%)					
Caucasian	280 (65.1)	62 (67.4)	90 (61.2)	60 (62.5)	68 (71.6)
African American	122 (28.4)	20 (21.7)	48 (32.7)	30 (31.3)	24 (25.3)
Hispanic/other	28 (6.5)	10 (10.9)	9 (6.1)	6 (6.3)	3 (3.2)
Employed, No. (%)	329 (76.5)	78 (73.9)	109 (74.2)	75 (78.1)	77 (81.0)
Cigarette smoker, No. (%)	19 (4.4)	3 (3.3)	8 (5.4)	2 (2.1)	6 (6.3)
History of Depression, No.(%)	128 (29.8)	27 (29.4)	41 (27.9)	24 (25.0)	36 (37.9)
Anti-depressant medication, No. (%)	78 (18.2)	17 (18.5)	27 (18.4)	18 (18.8)	16 (16.8)
Thyroid medication, No. (%)	65 (15.2)	13 (14.1)	18 (12.2)	16 (16.7)	18 (19.0)
Hormone therapy, No. (%)	196 (47.2)	48 (52.2)	62 (42.2)	42 (43.8)	44 (46.3)
Cardiovascular disease factors					
LDL-C, mg/dL	118.4 (26.4)	118.3 (26.4)	117.6 (27.2)	118.2 (25.3)	120.2 (26.7)
HDL-C, mg/dL	57.4 (14.3)	56.4 (13.3)	58.1 (14.5)	57.0 (15.2)	57.8 (14.0)
Triglycerides, mg/dL	129.2 (64.0)	133.9 (67.7)	130.0 (60.1)	127.8 (58.2)	124.9 (71.8)
Fasting glucose, mg/dL	94.7 (9.6)	95.1 (13.2)	94.4 (8.6)	94.6 (8.3)	95.1 (8.3)
Blood pressure, mm Hg					
Systolic	139.8 (13.0)	141.6 (12.2)	139.4 (13.2)	140.2 (13.5)	138.2 (12.9)
Diastolic	81.0 (8.5)	80.9 (7.8)	80.9 (9.0)	80.9(8.0)	81.0 (8.9)
Anthropometrics					
Weight, kg	84.6 (6.5)	86.4 (12.3)	83.4 (11.5)	85.2 (12.8)	84.3 (11.2)
Body mass index (kg/m <sup>2</sup> )	31.8 (3.8)	31.4 (3.6)	32.1 (4.1)	31.5 (3.7)	32.4 (3.9)

**NIH-PA** Author Manuscript

Characteristics	All participants (n= 430)	Control (n=92)	4 kcal/kg/wk (n= 147)	8 kcal/kg/wk (n=96)	12 kcal/kg/wk (n=95)
Quality of Life (SF-36)					
Physical QUL				010155	
Physical Functioning	/8.2 (18.6)	(8.9 (10.6)	(8.0 (19.3)	(0.12) 4.6/	80.8 (16.6)
Role Physical	75.5 (34.1)	78.8 (31.2)	72.8 (37.0)	77.6 (33.5)	74.5 (32.8)
Bodily Pain	70.7 (19.5)	69.8 (17.0)	71.4 (20.3)	72.0 (20.9)	69.2 (19.2)
General Health	72.0 (16.2)	70.9 (16.2)	72.9 (16.1)	70.5 (17.3)	73.3 (16.4)
Mental QOL					
Role Emotional	78.3 (33.9)	77.2 (36.3)	78.2 (34.6)	84.0 (29.8)	73.7 (34.0)
Social Functioning	84.8 (19.4)	83.4 (20.3)	85.7 (18.4)	87.6 (16.3)	81.8 (22.4)
Vitality	54.2 (20.3)	52.7(19.7)	54.5 (21.0)	56.3 (20.1)	53.1 (20.3)
Mental Health	77.7 (13.8)	76.6 (14.6)	78.1 (13.5)	78.5 (13.1)	77.3 (14.3)

SI conversions: To convert LDL-C and HDL-C to mmo/L multiply by 0.0259. To convert triglycerides to mmo/L multiply by 0.0113. To convert glucose to mmo/L multiply by 0.0555 cholesterol.

~
~
_
—
~
-
>
<u> </u>
1
÷÷-
2
utho
Ξ.
· ·
$\geq$
5
lan
L L
_
č.
<u> </u>
S
scr
<u> </u>
<u> </u>
<u> </u>

Mean (SD) exercise-related variables at baseline and change in exercise-related variables after exercise training. Table 2

			Rand	Randomization Groups	
	All (n= 430)	Control (n=92)	4 kcal/kg/wk (n= 147)	8 kcal/kg/wk (n=96)	12 kcal/kg/wk (n=95)
Exercise-related variables					
Baseline Peak relative VO2, ml/kg/min	15.4 (2.9)	15.5 (3.1)	15.5(3.0)	14.7 (2.5)	15.7 (3.0)
Change in Peak relative VO <sub>2</sub> , ml/kg/min	0.78 (1.9)	-0.30 (1.9)	0.65 (1.9)	1.33 (1.6)	1.52 (1.80)
6-mo Adherence (%) <sup>a</sup>	92.8 (20.4)	N/A	95.4 (15.5)	88.1 (26.4)	93.7(19.5)
Mean Number of Sessions per week	2.9	N/A	2.7	2.9	3.1
Time spent exercising (min/week) $b$	113.8 (61.3)	N/A	73.9 (15.5)	138.3 (25.3)	183.6 (43.3)

 $a^{d}$  Adherence was calculated for each individual by dividing the kilocalories expended during the 6-month exercise training by the kilocalories prescribed for the training period \*100.

b Data for individuals who completed the intervention. Data are for exercise training period excluding the initial ramping period, which represents 6 months of data for the 4-kcal/kg, 5 months for the 8kcal/kg, and 4 months for the 12-kcal/kg/wk groups.

NIH-PA Author Manuscript

8 September 2017 Sept

Martin et al.

	es by subgroups.
<b>`</b>	scores
225	f life (SF-36)
	of life (
	aseline quality of
	ã
	(SD)
	mean
	l fitted
	Unadjusted

Bachine Cancenover         N         Prysical Functioning         Role Physical         Bodily Pain         General Health         Role Eunofional         Social Functioning         Viaily         Meanal Health           Ennicity/Rase         280         76.4 ( $R_0 = 0$ 72.3 ( $S_0 = 7$ 73.3 ( $S_0 = 7$ 73.3 ( $S_0 = 7$ 73.4 ( $S_0 = 7$ 74.4 ( $S_0 = 7$				Physical Health Measures	Measures			Mental Health Measures	Measures	
30         764 (18.6) <sup>11</sup> 747 (33.7)         703 (18.9)         723 (15.6)         780 (33.4)         849 (19.5)         523 (19.7) <sup>11</sup> rieu         22         83.1 (15.1) <sup>10</sup> 75.3 (35.0)         71.5 (20.7)         708 (17.3)         83.3 (20.3)         57.1 (21.4) <sup>10</sup> Obler         28         83.1 (15.1) <sup>10</sup> 75.0 (33.4)         72.3 (20.0)         74.3 (17.1)         87.7 (12.3)         84.3 (21.0) <sup>10</sup> Obler         28         83.1 (15.1) <sup>10</sup> 75.0 (33.4)         72.3 (20.0)         74.3 (17.1)         87.7 (12.3)         84.3 (21.0) <sup>10</sup> 17.5         8         87.1 (12.1) <sup>10</sup> 72.3 (12.0) <sup>10</sup> 83.7 (12.3)         84.3 (21.0) <sup>10</sup> 17.6         77.3 (33.0)         60.1 (17.1) <sup>11</sup> 77.7 (33.0)         81.8 (20.0) <sup>10</sup> 54.1 (20.0)           17.5         78.1 (14.3)         73.1 (19.2)         76.7 (16.1) <sup>11</sup> 86.7 (17.3) <sup>10</sup> 84.1 (20.0)           60         70.0 (19.8) <sup>10</sup> 67.1 (19.2)         70.4 (19.3)         76.7 (16.1) <sup>11</sup> 87.7 (12.3)         84.1 (20.0)           8.         71.7 (18.0)         71.7 (18.0)         71.7 (13.0)         81.8 (20.8) <sup>10</sup> 84.1 (20.0)           8.         71.1 (18.0) <sup>11</sup> 71.7 (13.0)	Baseline Category	z	Physical Functioning	Role Physical	Bodily Pain	General Health	Role Emotional	Social Functioning	Vitality	Mental Health
280         764 (18.6) <sup>a</sup> 713 (33.7)         703 (18.9)         723 (15.6)         780 (13.3)         739 (35.5)         833 (20.1)         579 (21.0) <sup>b</sup> rrie         112         81.1 (15.1) <sup>ab</sup> 750 (35.4)         71.3 (00.7)         70.8 (17.3)         779 (35.5)         83.3 (10.1) <sup>ab</sup> 57.1 (21.4) <sup>ab</sup> Ohu         28         81.1 (15.1) <sup>ab</sup> 750 (35.4)         70.0 (19.6)         74.5 (17.7)         83.3 (22.1)         89.7 (12.3)         57.1 (21.4) <sup>ab</sup> Ohu         773 (87.3) <sup>a</sup> 74.7 (34.6)         70.0 (19.6)         72.0 (16.1) <sup>b</sup> 83.3 (21.2) <sup>b</sup> 54.1 (20.0)           66         700 (19.8) <sup>b</sup> 67.1 (39.2)         70.4 (19.3)         75.2 (16.1) <sup>b</sup> 80.6 (33.8)         83.2 (02.9) <sup>b</sup> 54.1 (20.7)           80         77.8 (18.7) <sup>a</sup> 74.7 (34.6)         70.4 (19.3)         75.2 (16.1) <sup>b</sup> 80.6 (33.8)         83.2 (02.9) <sup>b</sup> 54.1 (20.7) <sup>b</sup> 80         73.9 (16.1) <sup>b</sup> 76.7 (16.1) <sup>b</sup> 77.7 (33.0)         81.3 (10.9.7) <sup>a</sup> 54.1 (20.0)           90         73.9 (16.1) <sup>b</sup> 73.2 (15.0) <sup>b</sup> 73.2 (15.9) <sup>b</sup> 83.2 (17.3) <sup>b</sup> 84.1 (20.7) <sup>b</sup> 80         73.9 (16.1) <sup>b</sup> 76.7 (6.1) <sup>b</sup> 73.2	Ethnicity/Race									
arise         12         815 (150) <sup>b</sup> 775 (350)         713 (307)         708 (17.7)         833 (32.1)         873 (12.3)         573 (21.0) <sup>b</sup> Oble         28         811 (51.1) <sup>ab</sup> 750 (55.4)         720 (200)         745 (17.7)         833 (32.1)         873 (12.3)         573 (12.1) <sup>ab</sup> 175         814 (17.2) <sup>ab</sup> 730 (55.4)         700 (19.6)         732 (15.0) <sup>b</sup> 813 (20.3) <sup>ab</sup> 813 (20.0) <sup>b</sup>	Caucasian	280	76.4 (18.6) <sup>a</sup>	74.7 (33.7)	70.3 (18.9)	72.3 (15.6)	78.0 (33.4)	84.9 (19.5)	52.3 (19.7) <sup>a</sup>	77.4 (13.4)
Ohe         28         83.1 (15.1) <sup>10.10</sup> 75.0 (35.4)         7.0 (20.9)         74.5 (17.7)         83.3 (32.1)         89.7 (12.3)         57.1 (21.4) <sup>10.10</sup> 175         81.6 (17.2) <sup>10</sup> 7.0 (19.8) <sup>10</sup> 7.1 (16.95)         69.1 (17.1) <sup>10</sup> 77.7 (33.0)         81.8 (20.8) <sup>10</sup> 54.1 (20.0)           195         77.8 (18.7) <sup>10</sup> 7.1 (39.2)         7.0 (19.8) <sup>10</sup> 7.1 (16.9)         7.2 (16.1) <sup>10</sup> 81.2 (17.3) <sup>10</sup> 54.1 (20.0)           195         77.8 (18.7) <sup>10</sup> 77.1 (13.9)         76.7 (16.1) <sup>10</sup> 76.7 (16.1) <sup>10</sup> 87.2 (17.3) <sup>10</sup> 54.1 (20.0)           106         700 (19.8) <sup>10</sup> 77.1 (16.0)         77.6 (4.7)         85.1 (19.0)         54.1 (20.0)           101         79.9 (16.1)         76.0 (19.3)         70.4 (19.2)         70.4 (19.2)         54.1 (20.0)           101         79.9 (16.1)         76.4 (3.0)         71.7 (16.0)         77.6 (4.1)         85.1 (19.6)         54.1 (20.0)           101         79.9 (16.1)         76.4 (3.0)         71.7 (16.0)         79.2 (3.0)         84.2 (19.2)         56.1 (20.0)           102         79.9 (16.1)         79.2 (16.1)         84.2 (19.2)         85.0 (20.0)         86.1 (20.0)           102         7	African American	122	81.5 (18.9) <sup>b</sup>	77.5 (35.0)	71.3 (20.7)	70.8 (17.3)	77.9 (35.5)	83.3 (20.3)	57.9 (21.0) <sup>b</sup>	77.8 (14.9)
	Hispanic or Other	28	83.1 (15.1) <sup>ab</sup>	75.0 (35.4)	72.0 (20.9)	74.5 (17.7)	83.3 (32.1)	89.7 (12.3)	57.1 (21.4) <sup>ab</sup>	79.6 (12.5)
	Age Group									
	45-54 years	175	81.6 (17.2) <sup>a</sup>	79.3 (31.2)	71.6 (19.5)	69.1 (17.1) <sup>a</sup>	77.7 (33.0)	81.8 (20.8) <sup>a</sup>	54.3 (21.0)	76.3 (14.0)
	55-64 years	195	77.8 (18.7) <sup>a</sup>	74.7 (34.6)	70.0 (19.6)	73.2 (15.0) <sup>b</sup>	78.1 (34.8)	87.2 (17.3) <sup>b</sup>	54.1 (20.0)	78.2 (13.5)
Image: second	>65 years	60	70.0 (19.8) <sup>b</sup>	67.1 (39.2)	70.4 (19.3)	76.7 (16.1) <sup>b</sup>	80.6 (33.8)	85.8 (20.5) <sup>ab</sup>	54.1 (19.7)	79.6 (13.7)
	Smoking Habits									
	Never	307	78.0 (19.3)	76.0 (33.4)	70.6 (19.4) <sup>ab</sup>	71.7 (16.0)	77.6 (34.7)	85.1 (19.6)	54.1 (20.7)	77.7 (14.1)
	Former	104	79.9 (16.1)	76.4 (35.0)	73.1 (18.2) <sup>a</sup>	73.9 (16.6)	79.2 (32.6)	84.2 (19.2)	55.0 (20.0)	78.6 (12.5)
	Current	19	72.9 (19.2)	63.1 (40.3)	59.7 (24.9) <sup>b</sup>	66.6 (18.0)	84.2 (28.0)	82.9 (17.3)	50.8 (17.3)	72.0 (14.0)
3781.9 (14.3)81.8 (30.4)74.6 (18.7)68.9 (17.7)75.7 (32.1)78.4 (22.6)48.1 (23.4)39377.9 (18.9)74.9 (34.4)70.3 (19.6)72.3 (16.1)78.5 (34.1)85.4 (19.0)54.8 (20.0)35179.1 (18.0) <sup>a</sup> 77.2 (33.0) <sup>a</sup> 71.7 (18.9) <sup>a</sup> 73.4 (15.9) <sup>a</sup> 80.8 (32.2) <sup>a</sup> 86.1 (18.9) <sup>a</sup> 56.4 (20.0) <sup>a</sup> 7874.6 (20.7) <sup>b</sup> 67.9 (38.0) <sup>b</sup> 66.4 (21.5) <sup>b</sup> 65.7 (16.3) <sup>b</sup> 67.1 (38.9) <sup>b</sup> 78.8 (20.7) <sup>b</sup> 44.4 (19.2) <sup>b</sup>	Marital Status									
39377.9 (18.9)74.9 (34.4)70.3 (19.6)72.3 (16.1)78.5 (34.1)85.4 (19.0)54.8 (20.0)35179.1 (18.0) <sup>a</sup> 77.2 (33.0) <sup>a</sup> 71.7 (18.9) <sup>a</sup> 73.4 (15.9) <sup>a</sup> 80.8 (32.2) <sup>a</sup> 86.1 (18.9) <sup>a</sup> 56.4 (20.0) <sup>a</sup> 7874.6 (20.7) <sup>b</sup> 67.9 (38.0) <sup>b</sup> 66.4 (21.5) <sup>b</sup> 65.7 (16.3) <sup>b</sup> 67.1 (38.9) <sup>b</sup> 78.8 (20.7) <sup>b</sup> 44.4 (19.2) <sup>b</sup>	Not Married	37	81.9 (14.3)	81.8 (30.4)	74.6 (18.7)	68.9 (17.7)	75.7 (32.1)	78.4 (22.6)	48.1 (23.4)	75.5 (16.2)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Married	393	77.9 (18.9)	74.9 (34.4)	70.3 (19.6)	72.3 (16.1)	78.5 (34.1)	85.4 (19.0)	54.8 (20.0)	77.9 (13.5)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Antidepressant Use									
78 74.6 $(20.7)^{\text{b}}$ 67.9 $(38.0)^{\text{b}}$ 66.4 $(21.5)^{\text{b}}$ 65.7 $(16.3)^{\text{b}}$ 67.1 $(38.9)^{\text{b}}$ 78.8 $(20.7)^{\text{b}}$ 44.4 $(19.2)^{\text{b}}$	No	351	79.1 (18.0) <sup>a</sup>	77.2 (33.0) <sup>a</sup>	71.7 (18.9) <sup>a</sup>	73.4 (15.9) <sup>a</sup>	80.8 (32.2) <sup>a</sup>	86.1 (18.9) <sup>a</sup>	$56.4 (20.0)^{a}$	78.6 (13.7) <sup>a</sup>
	Yes	78	74.6 (20.7) <sup>b</sup>	67.9 (38.0) <sup>b</sup>	66.4 (21.5) <sup>b</sup>	65.7 (16.3) <sup>b</sup>	67.1 (38.9) <sup>b</sup>	78.8 (20.7) <sup>b</sup>	44.4 (19.2) <sup>b</sup>	73.3 (13.3) <sup>b</sup>

Mental Health Measures           Mole Emotional         Social Functioning         Vitality           76.2 (38.4)         84.0 (20.8)         54.1 (21.1)           78.9 (32.4)         85.0 (18.9)         54.2 (20.1)           78.9 (32.4)         85.0 (18.9)         54.2 (20.1)           78.1 (35.9)         86.8 (18.6)         55.8 (20.6)           75.1 (35.9)         86.8 (18.6)         55.8 (20.6)           76.1 (36.1)         82.2 (18.4)         51.2 (18.9)	Physical Health MeasuresMental Health MeasuresNotal FunctioningRole PhysicalBodity PainGeneral HealthRole EmotionalSocial FunctioningNotalPhysical FunctioningRole PhysicalBodity PainGeneral HealthRole EmotionalSocial Functioning10172.8 (21.5) $a$ 67.8 (40.5) $a$ 65.2 (20.9) $a$ 71.9 (16.4)76.2 (38.4)84.0 (20.8)32979.9 (17.3) $b$ 77.9 (31.6) $b$ 72.4 (18.8) $b$ 72.1 (16.2)78.9 (32.4)85.0 (18.9)11111379.9 (17.3) $b$ 77.9 (31.6) $b$ 72.1 (16.2)78.9 (32.4)84.6 (20.8)112183.1 (16.3) $a$ 79.0 (13.0) $a$ 72.1 (16.0) $a^{10}$ 75.1 (15.6) $a$ 84.6 (20.5)113183.1 (16.3) $a$ 79.0 (19.6) $b$ 71.1 (16.0) $a^{10}$ 82.3 (30.4)84.6 (20.5)113183.1 (16.3) $a$ 79.0 (19.6) $b$ 64.1 (19.6) $b$ 75.1 (15.6) $a$ 84.6 (20.5)113271972.0 (19.2) $a^{10}$ 75.1 (15.6) $a$ 75.1 (15.6) $b$ 84.6 (20.5)1137778 (18.4) $b$ 77.1 (33.2) $a^{10}$ 75.1 (16.6) $b$ 82.3 (30.4)84.6 (20.5)1137778 (18.4) $b$ 77.1 (33.2) $a^{10}$ 66.1 (19.6) $b$ 66.1 (16.6) $b$ 82.1 (8.6)1137778 (18.4) $b$ 77.1 (33.2) $a^{10}$ 75.1 (15.6) $b$ 75.1 (15.6) $b$ 84.6 (20.5)1137778 (18.4) $b$ 77.0 (19.5) $b$ 66.1 (19.6) $b$ 75.1 (16.9) $b$ 82.3 (30.4) $b$ 84.6 (20.5)113877.1 (33.2) $a^{10}$ 77.0 (19.5) $b$ </th <th>Physical Health MeasuresMental Health MeasuresBodity FainGeneral HealthRotal FunctioningVitalBaseline CategoryNPysical FunctioningRole PhysicalBodity PainGeneral HealthRole EmotionalSocial FunctioningVitalEmployed10172.8 (21.5) a67.8 (40.5) a65.2 (20.9) a71.9 (16.4)76.2 (38.4)84.0 (20.8)54.1 (20.8)No10172.8 (21.5) a67.3 (15.0) b72.4 (18.8) b72.1 (16.2)78.9 (32.4)84.0 (20.8)54.2 (20.8)No10172.8 (21.5) a67.3 (15.0) b72.1 (16.2)78.9 (32.4)84.0 (20.8)54.2 (20.8)No10172.8 (18.9) b72.1 (16.2)78.9 (32.4)84.0 (20.8)54.2 (20.8)Mental Realth11777.9 (31.6) b72.1 (16.2)78.9 (32.4)84.0 (20.8)54.2 (20.8)Mental Realth11777.8 (18.4) b72.1 (16.2) b75.1 (16.2)54.2 (20.8)54.2 (20.8)Mental Realth11777.8 (18.4) b72.1 (16.0) b75.1 (16.2) b54.2 (20.8)54.2 (20.8)Mental Realth11777.8 (18.4) b72.1 (16.2) b75.1 (16.5) b54.2 (20.8) b54.2 (20.8)Mental Realth11777.8 (18.4) b72.1 (16.0) b75.1 (16.5) b54.2 (20.8) b54.2 (20.8) bOverveight15177.1 (16.0) b75.1 (16.5) b75.1 (16.5) b54.2 (20.8) bMental Realth77.1 (16.8) b&lt;</th> <th>NIH-PA Author Manuscript</th> <th>Auth</th> <th>NIH-P/</th> <th>Iscript</th> <th><b>NIH-PA</b> Author Manuscript</th> <th>NIH-PA Au</th> <th></th> <th>NIH-PA Author Manuscript</th> <th>H-PA Auth</th> <th>IIN</th>	Physical Health MeasuresMental Health MeasuresBodity FainGeneral HealthRotal FunctioningVitalBaseline CategoryNPysical FunctioningRole PhysicalBodity PainGeneral HealthRole EmotionalSocial FunctioningVitalEmployed10172.8 (21.5) a67.8 (40.5) a65.2 (20.9) a71.9 (16.4)76.2 (38.4)84.0 (20.8)54.1 (20.8)No10172.8 (21.5) a67.3 (15.0) b72.4 (18.8) b72.1 (16.2)78.9 (32.4)84.0 (20.8)54.2 (20.8)No10172.8 (21.5) a67.3 (15.0) b72.1 (16.2)78.9 (32.4)84.0 (20.8)54.2 (20.8)No10172.8 (18.9) b72.1 (16.2)78.9 (32.4)84.0 (20.8)54.2 (20.8)Mental Realth11777.9 (31.6) b72.1 (16.2)78.9 (32.4)84.0 (20.8)54.2 (20.8)Mental Realth11777.8 (18.4) b72.1 (16.2) b75.1 (16.2)54.2 (20.8)54.2 (20.8)Mental Realth11777.8 (18.4) b72.1 (16.0) b75.1 (16.2) b54.2 (20.8)54.2 (20.8)Mental Realth11777.8 (18.4) b72.1 (16.2) b75.1 (16.5) b54.2 (20.8) b54.2 (20.8)Mental Realth11777.8 (18.4) b72.1 (16.0) b75.1 (16.5) b54.2 (20.8) b54.2 (20.8) bOverveight15177.1 (16.0) b75.1 (16.5) b75.1 (16.5) b54.2 (20.8) bMental Realth77.1 (16.8) b<	NIH-PA Author Manuscript	Auth	NIH-P/	Iscript	<b>NIH-PA</b> Author Manuscript	NIH-PA Au		NIH-PA Author Manuscript	H-PA Auth	IIN
N         Physical Functioning         Role Physical         Bodily Pain         General Health         Role Emotional         Social Functioning         Vitality           101         72.8 (21.5) <sup>a</sup> $67.8 (40.5) ^{a}$ $65.2 (20.9) ^{a}$ $71.9 (16.4)$ $76.2 (38.4)$ $84.0 (20.8)$ $54.1 (21.1)$ 101         72.8 (21.5) <sup>a</sup> $67.8 (40.5) ^{a}$ $65.2 (20.9) ^{a}$ $71.9 (16.2)$ $78.9 (32.4)$ $84.0 (20.8)$ $54.1 (21.1)$ 329         799 (17.3) <sup>b</sup> 77.9 (31.6) <sup>b</sup> 72.4 (18.8) <sup>b</sup> 72.1 (16.2) $78.9 (32.4)$ $85.0 (18.9)$ $54.2 (20.1)$ 101         72.8 (21.5) <sup>a</sup> 77.9 (31.6) <sup>b</sup> 72.1 (16.2) $78.9 (32.4)$ $85.0 (18.9)$ $54.2 (20.1)$ 111         83.1 (16.3) <sup>a</sup> 77.1 (33.2) <sup>ab</sup> 72.1 (16.2) <sup>a</sup> $75.1 (35.9) a$ $54.2 (20.8)$ 117         778 (18.4) <sup>b</sup> 77.1 (33.2) <sup>ab</sup> 72.1 (16.0) <sup>ab</sup> $82.3 (30.4)$ $84.6 (20.5) a$ $54.5 (20.6)$ 112         71.8 (18.4) <sup>b</sup> 77.1 (16.0) <sup>ab</sup> $75.1 (35.9) b$ $84.6 (20.5) c$ $54.5 (20.8)$ 102         71.9 (20.2) <sup>c</sup> $67.6 (19.0) b$	Baceline CategoryNPhysical FunctioningRole PhysicalBodily PainGeneral HealthRole EnotionalSocial FunctioningVitalityMental HealthEmployed $101$ $72.8 (12.5)^a$ $67.8 (40.5)^a$ $65.2 (20.9)^a$ $71.9 (16.4)$ $76.2 (38.4)$ $84.0 (20.8)$ $54.1 (21.1)$ $76.8 (14.2)$ No $101$ $72.8 (21.5)^a$ $67.8 (40.5)^a$ $72.4 (18.8)^b$ $72.1 (16.2)$ $78.9 (32.4)$ $84.0 (20.8)$ $54.1 (21.1)$ $76.8 (14.2)$ No $101$ $72.8 (21.5)^a$ $77.9 (31.6)^b$ $72.4 (18.8)^b$ $72.1 (16.2)$ $78.9 (22.4)$ $85.0 (18.9)$ $54.2 (20.1)$ $77.9 (13.6)$ Mental Hand $77.9 (16.2)^a$ $72.1 (16.2)$ $78.9 (22.4)$ $85.0 (18.9)$ $54.2 (20.1)$ $77.9 (13.6)$ Mental Hand $77.9 (16.2)^a$ $72.1 (16.2)^a$ $72.1 (16.2)^a$ $72.1 (15.0)^a$ $72.$	Baseline CategoryNPhysical FunctioningRole PhysicalBodity PainGeneral HealthRole EmotionalSocial FunctioningVitalEmployedEmployedNo10172.8 (21.5) a67.8 (40.5) a65.2 (20.9) a71.9 (16.4)76.2 (38.4)84.0 (20.8)54.1 (No10172.8 (21.5) a67.8 (40.5) a65.2 (20.9) a71.9 (16.4)76.2 (38.4)84.0 (20.8)54.1 (No10172.8 (21.5) a67.8 (40.5) a65.2 (20.9) a71.1 (16.2)78.9 (32.4)84.0 (20.8)54.2 (20.5)Nes32.979.9 (17.3) b77.9 (31.6) b72.1 (16.2)78.9 (32.4)84.0 (20.8)55.8 (BMI Range11777.8 (18.4) b75.1 (16.2) a75.1 (16.2) a75.1 (35.9)86.8 (18.6)55.8 (Overweight15183.1 (16.3) a79.0 (31.6) a75.1 (15.6) a75.1 (35.9)86.8 (18.6)55.8 (Obee Class I17777.8 (18.4) b77.1 (33.2) ab72.1 (16.0) ab82.3 (30.4)84.6 (20.5)54.5 (Obee Class II10271.9 (20.2) c65.1 (19.6) b69.1 (16.9) b76.1 (36.1)82.2 (18.4)51.2 (21.2) aNalues are expressed as unadjusted fittled means (SD). P values for group differences were assessed by analysis of variance using Bonferroni correction. For pairwise compania superscripts. For example, employed participants who were not working. Employed participants of on differ significantly from participants who were not working. Employed participants did not differ significantly from participants who were not working. Emplo				Physical Health	Measures			Mental Health N	Measures	
101       72.8 (21.5) <sup>a</sup> 67.8 (40.5) <sup>a</sup> 65.2 (20.9) <sup>a</sup> 71.9 (16.4)       76.2 (38.4)       84.0 (20.8)       54.1 (21.1)         329       79.9 (17.3) <sup>b</sup> 77.9 (31.6) <sup>b</sup> 72.4 (18.8) <sup>b</sup> 72.1 (16.2)       78.9 (32.4)       85.0 (18.9)       54.2 (20.1)         ht       151       83.1 (16.3) <sup>a</sup> 77.9 (31.6) <sup>b</sup> 72.4 (18.8) <sup>b</sup> 72.1 (16.2)       78.9 (32.4)       85.0 (18.9)       54.2 (20.1)         nt       151       83.1 (16.3) <sup>a</sup> 77.9 (31.6) <sup>b</sup> 72.1 (16.2) <sup>ab</sup> 72.1 (16.2)       78.9 (32.4)       86.8 (18.6)       55.8 (20.6)         iso       177       77.8 (18.4) <sup>b</sup> 77.1 (33.2) <sup>ab</sup> 72.1 (15.6) <sup>a</sup> 75.1 (15.6) <sup>a</sup> 75.1 (35.9)       86.8 (18.6)       55.8 (20.6)         iso       102       71.9 (20.2) <sup>c</sup> 67.6 (38.1) <sup>b</sup> 66.1 (19.6) <sup>b</sup> 69.1 (16.9) <sup>b</sup> 76.1 (36.1)       82.2 (18.4)       51.2 (18.9)	Imployed           No         101         72.8 (20.5) <sup>a</sup> 65.2 (20.9) <sup>a</sup> 71.9 (16.4)         76.2 (38.4)         84.0 (20.8)         54.1 (21.1)         76.8 (14.2)           No         101         72.8 (21.5) <sup>a</sup> 67.8 (40.5) <sup>a</sup> 65.2 (20.9) <sup>a</sup> 71.9 (16.2)         78.9 (32.4)         84.0 (20.8)         54.1 (21.1)         76.8 (14.2)           Nes         32.9         79.9 (17.3) <sup>b</sup> 77.9 (31.6) <sup>b</sup> 72.1 (16.2)         78.9 (32.4)         84.0 (20.8)         54.2 (20.1)         77.3 (15.3)           SMI Range           Overweight         151         37.1 (16.0) <sup>ab</sup> 75.1 (15.6) <sup>a</sup> 75.1 (15.6) <sup>a</sup> 75.3 (30.4)         84.6 (20.5)         77.3 (15.3)           Overweight         151         77.1 (16.0) <sup>ab</sup> 75.3 (30.4)         84.6 (20.5)         74.3 (15.6)           Overweight         17.1 (16.0) <sup>ab</sup> 75.1 (16.0) <sup>b</sup> 75.3 (30.4)         84.6 (20.5)         74.3 (12.5)           Overweight         77.1 (16.0) <sup>ab</sup> 75.1 (16.0)	Buployed         No       101       72.8 (21.5) <sup>a</sup> 67.8 (40.5) <sup>a</sup> 65.2 (20.9) <sup>a</sup> 71.9 (16.4)       76.2 (38.4)       84.0 (20.8)       54.1 (Colspa="6")         Ves       329       79.9 (17.3) <sup>b</sup> 77.9 (31.6) <sup>b</sup> 72.4 (18.8) <sup>b</sup> 54.1 (16.2)       58.4 (20.8)       54.2 (Colspa="6")         NI Range         Deerveight       151       83.1 (16.3) <sup>a</sup> 79.0 (31.6) <sup>a</sup> 75.3 (16.9) <sup>b</sup> 55.8 (Colspa="6")       75.1 (15.6) <sup>a</sup> 55.8 (Colspa="6")       55.8 (Colspa="6")       54.5 (Colspa="6")       57.5 (Colspa="6")	Baseline Category	z	Physical Functioning	Role Physical	Bodily Pain	General Health	Role Emotional	Social Functioning	Vitality	Mental Healt
101       72.8 (21.5) a $67.8 (40.5) a$ $65.2 (20.9) a$ $71.9 (16.4)$ $76.2 (38.4)$ $84.0 (20.8)$ $54.1 (21.1)$ 329       79.9 (17.3) b       77.9 (31.6) b       72.4 (18.8) b       72.1 (16.2)       78.9 (32.4) $85.0 (18.9)$ $54.2 (20.1)$ ht       151 $83.1 (16.3) a$ 79.0 (31.6) a       72.3 (19.5) a       75.1 (15.6) a       75.1 (35.9) $86.8 (18.6)$ $55.8 (20.6)$ ass       177       77.8 (18.4) b       77.1 (33.2) ab       72.0 (19.2) ab       71.1 (16.0) ab $82.3 (30.4)$ $84.6 (20.5)$ $54.5 (20.8)$ ass       102       71.9 (20.2) c $67.6 (33.1)^{b}$ $69.1 (19.6)^{b}$ $69.1 (16.9)^{b}$ $76.1 (36.1)$ $82.2 (18.4)$ $51.2 (18.9)$	No         101         72.8 (21.5) <sup>a</sup> 67.8 (40.5) <sup>a</sup> 65.2 (20.9) <sup>a</sup> 71.9 (16.4)         76.2 (38.4)         84.0 (20.8)         54.1 (21.1)         76.8 (14.2)           Ves         329         79.9 (17.3) <sup>b</sup> 77.9 (31.6) <sup>b</sup> 72.4 (18.8) <sup>b</sup> 72.1 (16.2)         78.9 (32.4)         85.0 (18.9)         54.2 (20.1)         77.9 (13.6)           BMI Range         Non-visitive state	No         101         72.8 (21.5) <sup>a</sup> $67.8 (40.5)^a$ $65.2 (20.9)^a$ 71.9 (16.4)         76.2 (38.4)         84.0 (20.8)         54.1 (54.1)           Yes         32.9         79.9 (17.3) <sup>b</sup> 77.9 (31.6) <sup>b</sup> 72.4 (18.8) <sup>b</sup> 72.1 (16.2)         78.9 (32.4)         85.0 (18.9)         54.2 (20.3)           BMI Range         Overweight         151         83.1 (16.3) <sup>a</sup> 79.0 (31.6) <sup>a</sup> 72.1 (15.6) <sup>a</sup> 75.1 (35.9)         86.8 (18.6)         55.8 (25.8)           Overweight         151         83.1 (16.3) <sup>a</sup> 79.0 (31.6) <sup>a</sup> 72.3 (19.5) <sup>a</sup> 71.1 (16.0) <sup>ab</sup> 75.1 (35.9)         86.8 (18.6)         55.8 (25.8)           Overweight         151         83.1 (16.3) <sup>a</sup> 72.0 (19.2) <sup>ab</sup> 71.1 (16.0) <sup>ab</sup> 75.1 (35.9)         86.8 (18.6)         55.8 (25.8)           Obese Class II         102         71.9 (20.2) <sup>c</sup> 66.1 (19.6) <sup>b</sup> 69.1 (16.9) <sup>b</sup> 76.1 (36.1)         82.2 (18.4)         81.2 (12.6)           Values are expressed as unadjusted fitted means (SD). P values for group differences were assessed by analysis of variance using Bonferroni correction. For pairwise comp SF-36 cacles, means that differ significantly ( $\rho < 0.6$ ) are noted with differences were assessed by analysis of variance using Bonferroni correction. For pairwise fomp SF-36 cacles, means that differ significantly $\rho < 0$	Employed									
329       79.9 (17.3) <sup>b</sup> 77.9 (31.6) <sup>b</sup> 72.4 (18.8) <sup>b</sup> 72.1 (16.2)       78.9 (32.4)       85.0 (18.9)       54.2 (20.1)         ht       151       83.1 (16.3) <sup>a</sup> 79.0 (31.6) <sup>a</sup> 72.3 (19.5) <sup>a</sup> 75.1 (15.6) <sup>a</sup> 75.1 (35.9)       86.8 (18.6)       55.8 (20.6)         ass       177       77.8 (18.4) <sup>b</sup> 77.1 (33.2) <sup>ab</sup> 72.0 (19.2) <sup>ab</sup> 71.1 (16.0) <sup>ab</sup> 82.3 (30.4)       84.6 (20.5)       54.5 (20.8)         ass       102       71.9 (20.2) <sup>c</sup> 67.6 (38.1) <sup>b</sup> 66.1 (16.0) <sup>b</sup> 76.1 (36.1)       82.2 (18.4)       51.2 (18.9)	Yes $329$ $79.9 (17.3)^{\text{b}}$ $77.9 (31.6)^{\text{b}}$ $72.4 (18.8)^{\text{b}}$ $72.1 (16.2)$ $78.9 (32.4)$ $85.0 (18.9)$ $54.2 (20.1)$ $77.9 (13.6)$ BMI Range         151 $83.1 (16.3)^{\text{a}}$ $79.0 (31.6)^{\text{a}}$ $75.1 (15.6)^{\text{a}}$ $75.1 (35.9)$ $86.8 (18.6)$ $55.8 (20.6)$ $77.3 (15.3)$ Overweight         151 $83.1 (16.3)^{\text{a}}$ $79.0 (31.6)^{\text{a}}$ $75.1 (15.6)^{\text{a}}$ $75.1 (35.9)$ $86.8 (18.6)$ $55.8 (20.6)$ $77.3 (15.3)$ Obset Class I         177 $77.3 (12.3)^{\text{ab}}$ $72.0 (19.2)^{\text{ab}}$ $71.1 (16.0)^{\text{ab}}$ $82.3 (30.4)$ $84.6 (20.5)$ $54.5 (20.8)$ $78.3 (12.5)$ Obset Class I         102         71.9 (20.2)^{\text{c}} $67.6 (38.1)^{\text{b}}$ $69.1 (16.9)^{\text{b}}$ $76.1 (36.1)$ $82.2 (18.9)$ $71.2 (18.9)$ $77.3 (12.6)$ Values are expressed as unadjusted fitted means (SD). P values for group differences were assessed by analysis of variance using Bonferoni correction. For pairwise comparisons within subroups SF-36 scales, means that differ significantly ( $p<.605$ ) are noted with different superscrips. For example, employed participants reported significantly showere not working. and bonput participants of QOL at baseline compared to participants who were not working. Emp	Yes         329         79.9 (17.3) <sup>b</sup> 77.9 (31.6) <sup>b</sup> 72.4 (18.8) <sup>b</sup> 72.1 (16.2)         78.9 (32.4)         85.0 (18.9)         54.3 (3.4)           BMI Range          151         83.1 (16.3) <sup>a</sup> 79.0 (31.6) <sup>a</sup> 72.3 (19.5) <sup>a</sup> 75.1 (15.6) <sup>a</sup> 75.1 (35.9)         86.8 (18.6)         55.8 (3.6)           Overweight         151         83.1 (16.3) <sup>a</sup> 79.0 (31.6) <sup>a</sup> 72.3 (19.2) <sup>ab</sup> 71.1 (16.0) <sup>ab</sup> 82.3 (30.4)         84.6 (20.5)         54.5 (3.5)           Obese Class I         177         77.8 (18.4) <sup>b</sup> 77.1 (33.2) <sup>ab</sup> 72.0 (19.2) <sup>ab</sup> 71.1 (16.0) <sup>ab</sup> 82.3 (30.4)         84.6 (20.5)         54.5 (3.5)           Obese Class I         102         71.9 (20.2) <sup>c</sup> 67.1 (19.6) <sup>b</sup> 69.1 (10.6) <sup>b</sup> 70.1 (36.1)         82.3 (30.4)         82.6 (20.5)         54.5 (	No	101	72.8 (21.5) <sup>a</sup>	67.8 (40.5) <sup>a</sup>	65.2 (20.9) <sup>a</sup>	71.9 (16.4)	76.2 (38.4)	84.0 (20.8)	54.1 (21.1)	76.8 (14.2)
ht       151       83.1 (16.3) <sup>a</sup> 79.0 (31.6) <sup>a</sup> 72.3 (19.5) <sup>a</sup> 75.1 (15.6) <sup>a</sup> 75.1 (35.9)       86.8 (18.6)       55.8 (20.6)         ass I       177       77.8 (18.4) <sup>b</sup> 77.1 (33.2) <sup>ab</sup> 71.1 (16.0) <sup>ab</sup> 82.3 (30.4)       84.6 (20.5)       54.5 (20.8)         ass II       102       71.9 (20.2) <sup>c</sup> 67.6 (33.1) <sup>b</sup> 69.1 (19.6) <sup>b</sup> 69.1 (16.9) <sup>b</sup> 76.1 (36.1)       82.2 (18.4)       51.2 (18.9)	BMI Range <b>Overweight</b> 15183.1 (16.3) $^{a}$ 79.0 (31.6) $^{a}$ 75.1 (15.6) $^{a}$ 75.1 (35.9)86.8 (18.6)55.8 (20.6)77.3 (15.3) <b>Overweight</b> 15183.1 (16.3) $^{a}$ 72.0 (19.2) $^{ab}$ 71.1 (16.0) $^{ab}$ 82.3 (30.4)84.6 (20.5)54.5 (20.8)78.3 (12.5) <b>Obse Class I</b> 17777.8 (18.4) $^{b}$ 77.1 (33.2) $^{ab}$ 72.0 (19.2) $^{ab}$ 69.1 (16.9) $^{b}$ 82.3 (30.4)84.6 (20.5)54.5 (20.8)77.0 (13.6) <b>Obsee Class II</b> 10271.9 (20.2) $^{c}$ 67.6 (38.1) $^{b}$ 69.1 (16.9) $^{b}$ 76.1 (36.1)82.2 (18.4)71.2 (18.9)77.0 (13.6)Values are expressed as unadjusted fitted means (SD). P values for group differences were assessed by analysis of variance using Bonferroni correction. For pairwise comparisons within subgroups SF-36 scales, means that differ significantly ( $\rho$ <.65) are noted with different superscripts. For example, employed participants reported significantly better physical functioning, role physical, and boole physical functioning and output spects of QOL at baseline compared to participants who were not working on any other SF-36 scales pain aspects of QOL at baseline compared to participants who were not working on any other SF-36 scales pain aspects of QOL at baseline compared to participants find porticipants field not differ significantly from participants who were not working on any other SF-36 scales pain aspects of QOL at baseline compared to participants who were not working on any other SF-36 scales pain aspects of QOL at baseline compared to participants identicipants did not differ significantly from participants who were not working on any other	BMI RangeOverweight15183.1 (16.3) a79.0 (31.6) a72.3 (19.5) a75.1 (15.6) a75.1 (35.9)86.8 (18.6)55.8 (Colspan="6")Overweight11777.1 (33.2) ab72.0 (19.2) ab71.1 (16.0) ab82.3 (30.4)84.6 (20.5)54.5 (Colspan="6")Obese Class I10271.9 (20.2) c67.6 (38.1) b66.1 (19.6) b76.1 (16.0) b76.1 (36.1)82.2 (18.4)51.2 (Values are expressed as unadjusted fitted means (SD). P values for group differences were assessed by analysis of variance using Bonferroni correction. For pairwise composed seares the means (SD). P values for group differences were assessed by analysis of variance using Bonferroni correction. For pairwise composed seares, means that differ significantly ( $p < 05$ ) are noted with different superscripts. For example, employed participants reported significantly better physical function pain aspects of QOL at baseline compared to participants who were not working. Employed participants did not differ significantly from participants who were not working.	Yes	329	79.9 (17.3) <sup>b</sup>	77.9 (31.6) <sup>b</sup>	72.4 (18.8) <sup>b</sup>	72.1 (16.2)	78.9 (32.4)	85.0 (18.9)	54.2 (20.1)	77.9 (13.6)
151       83.1 (16.3) <sup>a</sup> 79.0 (31.6) <sup>a</sup> 72.3 (19.5) <sup>a</sup> 75.1 (15.6) <sup>a</sup> 75.1 (35.9)       86.8 (18.6)       55.8 (20.6)         177       77.8 (18.4) <sup>b</sup> 77.1 (33.2) <sup>ab</sup> 72.0 (19.2) <sup>ab</sup> 71.1 (16.0) <sup>ab</sup> 82.3 (30.4)       84.6 (20.5)       54.5 (20.8)         1       102       71.9 (20.2) <sup>c</sup> 67.6 (38.1) <sup>b</sup> 66.1 (19.6) <sup>b</sup> 69.1 (16.9) <sup>b</sup> 76.1 (36.1)       82.2 (18.4)       51.2 (18.9)	Overweight         151         83.1 (16.3) $^{a}$ 79.0 (31.6) $^{a}$ 72.3 (19.5) $^{a}$ 75.1 (15.6) $^{a}$ 75.1 (35.9)         86.8 (18.6)         55.8 (20.6)         77.3 (15.3)           Obese Class I         177         77.8 (18.4) $^{b}$ 77.1 (33.2) $^{ab}$ 72.0 (19.2) $^{ab}$ 71.1 (16.0) $^{ab}$ 82.3 (30.4)         84.6 (20.5)         54.5 (20.8)         78.3 (12.5)           Obese Class II         102         71.9 (20.2) $^{c}$ 67.6 (38.1) $^{b}$ 69.1 (19.6) $^{b}$ 76.1 (36.1)         82.2 (18.4)         51.2 (18.9)         77.0 (13.6)           Values are expressed as unadjusted fitted means (SD). P values for group differences were assessed by analysis of variance using Bonferroni correction. For pairwise comparisons within subgroups SF-36 scales, means that differ significantly ( $p<.05$ ) are noted with different superscripts. For example, employed participants reported significantly better physical, and bos pair aspects of QOL at baseline compared to participants who were not working on any other SF-36 scale         76.0 (13.6)	Overweight         151         83.1 (16.3) <sup>a</sup> 79.0 (31.6) <sup>a</sup> 72.3 (19.5) <sup>a</sup> 75.1 (15.6) <sup>a</sup> 75.1 (35.9)         86.8 (18.6)         55.8 (37.6)           Obese Class I         177         77.8 (18.4) <sup>b</sup> 77.1 (33.2) <sup>ab</sup> 72.0 (19.2) <sup>ab</sup> 71.1 (16.0) <sup>ab</sup> 82.3 (30.4)         84.6 (20.5)         54.5 (37.6)           Obese Class I         102         71.9 (20.2) <sup>c</sup> 67.6 (38.1) <sup>b</sup> 66.1 (19.6) <sup>b</sup> 69.1 (16.9) <sup>b</sup> 76.1 (36.1)         82.2 (18.4)         51.2 (37.6)           Obese Class II         102         71.9 (20.2) <sup>c</sup> 67.6 (38.1) <sup>b</sup> 66.1 (16.9) <sup>b</sup> 76.1 (36.1)         82.2 (18.4)         51.2 (37.6)           Values are expressed as unadjusted fitted means (SD). P values for group differences were assessed by analysis of variance using Bonferroni correction. For pairwise compose scales, means that differ significantly ( $\gamma < 05$ ) are noted with different superscripts. For example, employed participants reported significantly better physical function pain aspects of QOL at baseline compared to participants who were not working. Employed participants did not differ significantly from participants who were not working.	BMI Range									
177       77.8 (18.4) b       77.1 (33.2) ab       72.0 (19.2) ab       71.1 (16.0) ab       82.3 (30.4)       84.6 (20.5)       54.5 (20.8)         I       102       71.9 (20.2) c       67.6 (38.1) b       66.1 (19.6) b       69.1 (16.9) b       76.1 (36.1)       82.2 (18.4)       51.2 (18.9)	<b>Obese Class I</b> $177$ $77.8 (18.4)^{b}$ $77.1 (33.2)^{ab}$ $72.0 (19.2)^{ab}$ $71.1 (16.0)^{ab}$ $82.3 (30.4)$ $84.6 (20.5)$ $54.5 (20.8)$ $78.3 (12.5)$ <b>Obese Class II</b> $102$ $71.9 (20.2)^{c}$ $67.6 (38.1)^{b}$ $66.1 (19.6)^{b}$ $69.1 (16.9)^{b}$ $76.1 (36.1)$ $82.2 (18.4)$ $51.2 (18.9)$ $77.0 (13.6)$ Values are expressed as unadjusted fitted means (SD). P values for group differences were assessed by analysis of variance using Bonferroni correction. For pairwise comparisons within subgroupsSF-36 scales, means that differ significantly ( $p<0$ ) are noted with different superscripts. For example, employed participants reported significantly better physical functioning, role physical, and boo pain aspects of QOL at baseline compared to participants who were not working. Employed participants did not differ significantly from participants who were not working on any other SF-36 scale	<b>Obese Class I</b> 17777.8 ( $18.4$ ) <sup>b</sup> 77.1 ( $33.2$ ) <sup>ab</sup> 72.0 ( $19.2$ ) <sup>ab</sup> 71.1 ( $16.0$ ) <sup>ab</sup> 82.3 ( $30.4$ )84.6 ( $20.5$ )54.5 ( $34.5$ ) <b>Obese Class II</b> 10271.9 ( $20.2$ ) <sup>c</sup> 67.6 ( $38.1$ ) <sup>b</sup> 66.1 ( $19.6$ ) <sup>b</sup> 69.1 ( $16.9$ ) <sup>b</sup> 76.1 ( $36.1$ )82.2 ( $18.4$ )51.2 ( $31.2$ ) <sup>c</sup> Values are expressed as unadjusted fitted means (SD). P values for group differences were assessed by analysis of variance using Bonferroni correction. For pairwise comp.SF-36 scales, means that differ significantly ( $\gamma < 05$ ) are noted with different superscripts. For example, employed participants reported significantly better physical function pain aspects of QOL at baseline compared to participants who were not working. Employed participants did not differ significantly from participants who were not working.	Overweight	151	83.1 (16.3) <sup>a</sup>	79.0 (31.6) <sup>a</sup>	72.3 (19.5) <sup>a</sup>	75.1 (15.6) <sup>a</sup>	75.1 (35.9)	86.8 (18.6)	55.8 (20.6)	77.3 (15.3)
102 71.9 (20.2) $^{\circ}$ 67.6 (38.1) $^{b}$ 66.1 (19.6) $^{b}$ 69.1 (16.9) $^{b}$ 76.1 (36.1) 82.2 (18.4) 51.2 (18.9)	<b>Obese Class II</b> $102$ $71.9 (20.2)^{c}$ $67.6 (38.1)^{b}$ $66.1 (19.6)^{b}$ $69.1 (16.9)^{b}$ $76.1 (36.1)$ $82.2 (18.4)$ $51.2 (18.9)$ $77.0 (13.6)$ Values are expressed as unadjusted fitted means (SD). P values for group differences were assessed by analysis of variance using Bonferroni correction. For pairwise comparisons within subgroupsSF-36 scales, means that differ significantly ( $p<05$ ) are noted with different superscripts. For example, employed participants reported significantly better physical functioning, role physical, and bopain aspects of QOL at baseline compared to participants who were not working. Employed participants did not differ significantly from participants who were not working on any other SF-36 scale	<b>Obese Class II</b> $102$ $71.9 (20.2)^c$ $67.6 (38.1)^b$ $66.1 (19.6)^b$ $69.1 (16.9)^b$ $76.1 (36.1)$ $82.2 (18.4)$ $51.2 (1.2)^c$ Values are expressed as unadjusted fitted means (SD). P values for group differences were assessed by analysis of variance using Bonferroni correction. For pairwise comp.SF-36 scales, means that differ significantly ( $p<05$ ) are noted with different superscripts. For example, employed participants reported significantly better physical function pain aspects of QOL at baseline compared to participants who were not working. Employed participants did not differ significantly from participants who were not working.ST-36 scales, means that differ significantly better physical function	<b>Obese Class I</b>	177	77.8 (18.4) <sup>b</sup>	77.1 (33.2) <sup>ab</sup>	72.0 (19.2) <sup>ab</sup>	71.1 (16.0) <sup>ab</sup>	82.3 (30.4)	84.6 (20.5)	54.5 (20.8)	78.3 (12.5)
	Values are expressed as unadjusted fitted means (SD). P values for group differences were assessed by analysis of variance using Bonferroni correction. For pairwise comparisons within subgroups SF-36 scales, means that differ significantly ( <i>p</i> <.05) are noted with different superscripts. For example, employed participants reported significantly better physical functioning, role physical, and bo pain aspects of QOL at baseline compared to participants who were not working. Employed participants did not differ significantly from participants who were not working on any other SF-36 scale pain aspects of QOL at baseline compared to participants who were not working. Employed participants did not differ significantly from participants who were not working on any other SF-36 scale pain aspects of QOL at baseline compared to participants who were not working. Employed participants did not differ significantly from participants who were not working on any other SF-36 scale pain aspects of QOL at baseline compared to participants who were not working.	Values are expressed as unadjusted fitted means (SD). P values for group differences were assessed by analysis of variance using Bonferroni correction. For pairwise compt SF-36 scales, means that differ significantly ( <i>p</i> <.05) are noted with different superscripts. For example, employed participants reported significantly better physical function pain aspects of QOL at baseline compared to participants who were not working. Employed participants did not differ significantly from participants who were not working.	<b>Obese Class II</b>	102	71.9 (20.2) <sup>c</sup>	67.6 (38.1) <sup>b</sup>	66.1 (19.6) <sup>b</sup>	69.1 (16.9) <sup>b</sup>	76.1 (36.1)	82.2 (18.4)	51.2 (18.9)	77.0 (13.6)
			SF-36 scales, meau pain aspects of QC	ns that diffe )L at baseli.	Presidential to $(p<.05)$ are a ne compared to participant:	noted with different s who were not worl	superscripts. For e king. Employed pa	xample, employed participants did not dif	articipants reported si Ter significantly from	gnificantly better physica participants who were no	al functioning, role ot working on any	physical, and book other SF-36 scal
SF-36 scales, means that differ significantly ( <i>p</i> <.05) are noted with different superscripts. For example, employed participants reported significantly better physical functioning, role physical, and b pain aspects of QOL at baseline compared to participants who were not working. Employed participants did not differ significantly from participants who were not working on any other SF-36 sc												
SF-36 scales, means that differ significantly ( <i>p</i> <.05) are noted with different superscripts. For example, employed participants reported significantly better physical functioning, role physical, and b pain aspects of QOL at baseline compared to participants who were not working on any other SF-36 sc												